Q2 2024 Syndax Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Syndax Pharmaceuticals Inc (SNDX) is on the verge of becoming a commercial stage company with anticipated FDA approvals for revumenib and axatilimab.
- The company has achieved several clinical milestones, including positive data from the BEAT AML and AUGMENT-102 trials, supporting revumenib's potential.
- Syndax is financially strong with $455 million in cash, expected to provide sufficient capital through 2026.
- The company has a robust clinical development strategy for revumenib and axatilimab, aiming to expand their use in combination with standard-of-care medicines.
- Syndax has prepared extensively for the commercial launch, with a trained sales team and advanced data mining capabilities to identify patient needs.
- The FDA extended the PDUFA action date for revumenib, delaying its potential approval by three months.
- There is uncertainty regarding the exact timing of the revumenib approval, which could impact the launch schedule.
- The company faces challenges in educating the market about the novel mechanism of menin inhibition.
- Syndax's commercial launch plans depend heavily on the success of partnerships, such as with Incyte for axatilimab.
- The company has not provided specific guidance on the timing of data releases for some ongoing trials, creating uncertainty for investors.
Good day, everyone, and welcome to the Syndax second quarter 2024 earnings conference call. Today's call is being recorded. (Operator Instructions)
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's second quarter 2024 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; Steve Closter, Chief Commercial Officer; and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer.
This call is accompanied by a slide deck that has been posted on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
